Johnson & Johnson's nipocalimab, a novel FcRn blocker, met its primary endpoint by significantly reducing disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) at 24 weeks, with benefits sustained through 52 weeks in a Phase 2 study. The drug targets pathogenic IgG autoantibodies while preserving immune function and showed greater efficacy in autoantibody-positive patients, who make up about 80% of SLE cases. Nipocalimab's safety profile was consistent with previous studies, and the drug has received Fast Track designation by the FDA. A Phase 3 trial is currently recruiting participants to further evaluate its potential as a targeted treatment for SLE, a chronic autoimmune disease that can cause severe organ damage and reduced quality of life.
Johnson & Johnson announced new Phase 2 data for nipocalimab, an immunoselective FcRn blocker, showing greater clinical response in Sjögren's disease patients with elevated autoantibodies and IgG levels. The drug reduced disease activity and symptoms...
Nanobiotix completed a €86.1 million follow-on offering in May 2026 to accelerate development of its nanotherapeutic platforms. New data from its Phase 2 study of JNJ-1900 (NBTXR3) in Stage 3 inoperable non-small cell lung cancer showed promising res...
Legend Biotech, a leader in cell therapy, reported that its CAR-T treatment CARVYKTI generated nearly $2 billion in sales in 2025. CARVYKTI, developed and co-promoted with Johnson & Johnson, is a one-time infusion therapy for multiple myeloma and has...
Johnson & Johnson's Phase 3 PROTEUS study shows ERLEADA (apalutamide) combined with hormone therapy before and after surgery significantly improves outcomes for high-risk localized prostate cancer patients. The treatment increased the chance of minim...
Johnson & Johnson reported that subcutaneous amivantamab, a dual EGFR and MET inhibitor, achieved a 42% overall response rate in patients with advanced head and neck squamous cell carcinoma previously treated with immunotherapy and chemotherapy. More...
